



US009326945B2

(12) **United States Patent**  
**Patel et al.**

(10) **Patent No.:** **US 9,326,945 B2**  
(45) **Date of Patent:** **May 3, 2016**

(54) **APIXABAN FORMULATIONS**

(75) Inventors: **Jatin Patel**, West Windsor, NJ (US);  
**Charles Frost**, Yardley, PA (US);  
**Jingpin Jia**, Belle Mead, NJ (US);  
**Chandra Vemavarapu**, Hillsborough,  
NJ (US)

(73) Assignees: **Bristol-Myers Squibb Company**,  
Princeton, NJ (US); **Pfizer Inc.**, New  
York, NY (US)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/579,796**

(22) PCT Filed: **Feb. 24, 2011**

(86) PCT No.: **PCT/US2011/025994**

§ 371 (c)(1),  
(2), (4) Date: **Oct. 10, 2012**

(87) PCT Pub. No.: **WO2011/106478**

PCT Pub. Date: **Sep. 1, 2011**

(65) **Prior Publication Data**

US 2013/0045245 A1 Feb. 21, 2013

#### Related U.S. Application Data

(60) Provisional application No. 61/308,056, filed on Feb.  
25, 2010.

(51) **Int. Cl.**

**A61K 9/20** (2006.01)  
**A61K 31/4545** (2006.01)  
**A61K 31/437** (2006.01)  
**A61K 31/4412** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 9/2018** (2013.01); **A61K 9/2013**  
(2013.01); **A61K 9/2054** (2013.01); **A61K**  
**9/2095** (2013.01); **A61K 31/4545** (2013.01);  
**A61K 31/437** (2013.01); **A61K 31/4412**  
(2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

6,150,366 A	11/2000	Arenson et al.
6,967,208 B2	11/2005	Pinto et al.
7,396,932 B2	7/2008	Shapiro et al.
2006/0069258 A1	3/2006	Shapiro et al.

(Continued)

#### FOREIGN PATENT DOCUMENTS

CN	1578660 A	2/2005
CN	101516355 A	8/2009

(Continued)

#### OTHER PUBLICATIONS

Official Action in Mexican Application No. MX/2012/060772  
(issued Jun. 14, 2013).

(Continued)

*Primary Examiner* — Bethany Barham

*Assistant Examiner* — Barbara Frazier

(74) *Attorney, Agent, or Firm* — Fitzpatrick, Cella, Harper &  
Scinto

(57) **ABSTRACT**

Compositions comprising crystalline apixaban particles hav-  
ing a  $D_{90}$  equal to or less than 89  $\mu\text{m}$ , and a pharmaceutically  
acceptable carrier, are substantially bioequivalent and can be  
used to for the treatment and/or prophylaxis of thromboem-  
bolic disorders.

**38 Claims, 4 Drawing Sheets**

Dissolution Rates of 2.5-mg Apixaban Tablets Using Drug Substance  
of Different Particle Size

